Meta-Analysis: Intravenous Versus Subcutaneous Infliximab in Inflammatory Bowel Disease.

ABSTRACT:

Background

Subcutaneous infliximab may provide multiple benefits over intravenous formulations. However, there is uncertainty about the relative efficacy in inflammatory bowel disease (IBD).

Aim

To evaluate the relative efficacy of intravenous versus subcutaneous infliximab in patients with IBD using clinical response, clinical remission, and endoscopic remission outcomes at 30- and 54-week outcomes.

Methods

We conducted a systematic review and network meta-analysis with results up to August 2024. We calculated comparative efficacy using surface under the cumulative ranking curve (SUCRA), posterior probability, and contrast plots.

Results

A total of 9 studies with 2519 patients met the selection criteria for inclusion; 33.6% (846/2519) of patients had Crohn's d

SUBMITTER: Chetwood JD 

PROVIDER: S-EPMC12287884 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature